Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer
Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer
复制标题
DOI：
10.1016/s0140-6736(00)02261-3
复制
发表时间：
2000-05-20
期刊：
影响因子：
168.9
通讯作者：
Iacopetta, B
中科院分区：
文献类型：
--
作者：
Elsaleh, H;Joseph, D;Iacopetta, B
背景 辅助化疗可以提高 Dukes' C 结直肠癌的 5 年生存率。需要改进对辅助治疗有反应的患者的选择。我们研究了肿瘤起源部位、性别和微卫星不稳定性 (MSI) 表型的存在是否与辅助化疗的生存获益相关。方法我们分析了 656 名连续的 Dukes' C 结直肠癌患者的数据，中位随访时间为 54 个月（范围 7-104），平均年龄 66.7 岁（SD 12.9）。我们通过 PCR 筛选肿瘤样本中 BAT-26 单核苷酸重复序列的缺失，以确定 MSI 状态。化疗和生存的详细信息是通过审查医院和卫生部门的记录获得的。对 272 名 (42%) 名患者进行了辅助化疗（氟尿嘧啶和左旋咪唑）以达到治愈目的。结果显示，与未接受辅助化疗的患者相比，患有右侧肿瘤并接受辅助化疗的患者具有显着的生存获益（研究结束时存活率为 48% vs 27% [95% CI 0.25-0.56]，p
Background Adjuvant chemotherapy can improve 5-year survival in Dukes' C colorectal carcinoma. Improved selection of patients who will respond to adjuvant treatments is required. We investigated whether site of tumour origin, sex, and presence of microsatellite instability (MSI) phenotype were associated with a survival benefit from adjuvant chemotherapy.Methods We analysed data for 656 consecutive patients with Dukes' C colorectal carcinoma, with median follow-up of 54 months (range 7-104) and mean age 66.7 years (SD 12.9). We screened tumour samples by PCR for deletions in the BAT-26 mononucleotide repeat to establish MSI status. Details of chemotherapy and survival were obtained by review of hospital and health-department records. Adjuvant chemotherapy (fluorouracil and levamisole) was given with curative intent to 272 (42%) patients.Findings Striking survival benefits were seen for patients who had right-sided tumours and who received adjuvant chemotherapy compared with those who did not (48 vs 27% alive at end of study [95% CI 0.25-0.56], p